Tumor suppressor KEAP1 promotes HSPA9 degradation, controlling mitochondrial biogenesis in breast cancer
Bing Han, Fang Zhen, Yue Sun, Bin Sun, Hongyi Wang, Wei Liu, Jian Huang, Xiao Liang, Yaru Wang, Xuesong Chen, Shui-Jie Li, Jing Hu
Abstract
The oxidative-stress-related protein Kelch-like ECH-associated protein 1 (KEAP1) is a substrate articulator of E3 ubiquitin ligase, which plays an important role in the ubiquitination modification of proteins. However, the function of KEAP1 in breast cancer and its impact on the survival of patients with breast cancer remain unclear. Our study demonstrates that KEAP1, a positive prognostic factor, plays a crucial role in regulating cell proliferation, apoptosis, and cell cycle transition in breast cancer. We investigate the underlying mechanism using human tumor tissues, high-throughput detection technology, and a mouse xenograft tumor model. KEAP1 serves as a key regulator of cellular metabolism, the reprogramming of which is one of the hallmarks of tumorigenesis. KEAP1 has a significant effect on mitochondrial biogenesis and oxidative phosphorylation by regulating HSPA9 ubiquitination and degradation. These results suggest that KEAP1 could serve as a potential biomarker and therapeutic target in the treatment of breast cancer. • KEAP1 inhibits breast cancer proliferation and malignant transformation • KEAP1 negatively regulates mitochondrial biogenesis • KEAP1 interacts with HSPA9 and promotes its degradation through ubiquitination • HSPA9 is required for KEAP1-regulated mitochondrial biogenesis in breast cancer Han et al. demonstrate that KEAP1 serves as a key regulator of cellular metabolism. KEAP1 has a significant effect on mitochondrial biogenesis and oxidative phosphorylation by regulating HSPA9 ubiquitination and degradation. These results suggest that KEAP1 could serve as a potential biomarker and therapeutic target in the treatment of breast cancer.